Method of producing pyrrolobenzimidazols or their tautomers, or their physiologically compatible sal

专利摘要:

公开号:SU1470191A3
申请号:SU864012604
申请日:1986-01-17
公开日:1989-03-30
发明作者:Мертенс Альфред；Хельк Йенс-Петер；Бергер Херберт；Мюллер-Бекманн Бернд；Штрайн Клаус；Реш Эгон
申请人:Берингер Маннхайм Гмбх (Фирма)；
IPC主号:

专利说明:

H
n
one
The invention relates to methods for producing new biologically active chemical compounds, namely, new pyrrolobenzimidazoles or their tautomers or their physiological combinations.

CM
reproducible salts of inorganic acids with the ability to increase the strength of heart contractions. This property suggests the possibility of using these compounds in medicine.
The purpose of the invention is to obtain new derivatives of pyrprobenzimidiol, possessing the ability to increase the strength of heart contractions, i.e. activity not characteristic of this range of compounds.
Example 1. 7.7 - Dimethyl-2- - (2-thieshsh) 6,7-dihydro-3N, 3N-3-2,3-benzo-midazol-6-one.
A solution of 3.8 g (20 mmol) of 5.6-diamine-3, 3-dimethylindolin-2-one, 2.25 g (20 mmol) of thiophene-2-alde: hydroxide in 4 ml of glacial acetic acid: in 40 MP of ethanol is heated. (For 1 hour at the temperature of refluxing the boil, and then heated; it is heated at the boiling point, while air is passed. After that, the reaction mixture is evaporated to dryness, and the resulting residue is mixed with ethyl alcohol. acetic acid and filtered. The crystalline product is recrystallized from acetone. Yield 1.7 g (30% of theoretically calculated value). T. Ш1. 332- 336 ° e.
PRI mme JP 2. 7,7-Dimetsh1-2- (2- -pyrrolyl) -6,7-dihydro-3N, 5H-pyrrolo 2,3-f benzimidazol-6-one.
The example is carried out analogously to example 1, out of 3.8 g (20 mmop) 5, b-diamino-3,3-dimethyl alkol-2-one, 1.9 g (20 mmol) pyrrol-2-aladehyde, and 0.4 g (2 mmol) para-toluenesulfr-acid is obtained after acidification and evaporation the crude product, which is the title compound. For the purpose of purification, the residue is treated with water, the filtrate is neutralized by killing 2N. ammonia, after which the product is filtered off and then recrystallized from Lri isopropyl alcohol by adding a solution of hydrogen chloride in ethanol. Yield 1.2 g (20% of theoretically calculated value). T. pl. hydrochloride.
Example 3. 7,7-Dimethyl-2- .-: (2-pyrazinyl) -6,7-dig1Vdro-3N, 3N-β-pyrrapo 2,3-benzimidazole-6-oi.
5., 1 g (26 mmol) of 5,6-diamino-3,3-dimethyl-Shnapin-2-one is dissolved in 100 ml of methylene chloride, after which the prepared solution is mixed with 5.5 g (39 mm of hydrochloride pyrazii-2-carboxylic acid and 3.9 g (39 mmop) of triethylamine, Reak
The mixture was kept for 1 hour, then the solvent was distilled off, and the residue was treated with water and filtered. The resulting product, consisting of monoamide and diamide, is recrystallized from a mixture of ethyl ester of acetic acid and methyl alcohol.
Exit 5.7 g. T. pl. 269-272 ° C. 5.6 g of mono- and diamide are stirred for 18 hours with 85 ml of ethyl alcohol and 85 ml of concentrated hydrochloric acid at 90 ° C. Immediately after this, the reaction mixture is evaporated, the residue is neutralized by the addition of 2 n. ammonia, after which the product is filtered. The product is purified on silica gel (eluent: methylene chloride and methyl alcohol in a ratio of 19: 1), and then recrystallized from a mixture of ethyl acetate and methyl alcohol.
Yield 0.85 g (16% of theoretically calculated value). T. pl.
.
Example 4. 7,7-Dimethyl-2- - (4-Thiazolyl) -6,7-dihydro-3H, 5H-pyrrolo 2,3-f benzimidazol-6-one.
The example is carried out analogously to example 3 with the use of 3.8 g (20 mmol) of 5,6-diamino-3, 3-dimeshshndolin-2- -one and 4.4 g (30 mmol) of thiazole chloride as the starting materials. 4-carboxylic acid gives the title compound.
Yield t, 9 g (33% of theoretically calculated value). T. pl.
280 ° C (from methyl alcohol).
Example 5. 7,7-Dimethyl-2- - (4-pyridazinyl), 7-dihydro-3H, 5H- -pyrrolo-C2,3-f1 benzimBDasop-6-one.
5.4 g (40 mmol) of 1-hydroxy-1H-benzotriazole are placed with 5 g of sulfuric calcium and 4.3 g (35 mmol) of 4-carboxylic acid pyridazine in absolute dimethylformamide. At Q ° C, 8.3 g (40 mmyl) of H, K-dicyclohexylcarbodiimide in a small amount of dimethylformamide is added dropwise to the prepared mixture. After the formation of the activated ester is complete, 5.7 g (30 mmol) of 5,6-di-3,3-dimesh1INdapin-2-one are added to the mixture and further stirred in one chenzo. 30 min. Immediately after
51470191
Rhixon 70 mg (25% of theoretical dimethylformamide distilled out the "calculated value). T. pl. high vacuum, the treatment residue is dioxane).
8. 7,7-Dimethyl-2 L4 f f j f - y -
YT with water, after which the crude product consisting of monoamide and dicyclohexyl urea is filtered off and used for further processing without further purification. Exit 20 g
The residue obtained is mixed with 200 MP of ethyl alcohol and 40 ml of concentrated hydrochloric acid, after which the mixture is heated at reflux for 2 hours. After cooling, the dicyclohexyl urea is filtered off and the ethanol solution is evaporated in vacuo. The residue obtained is suspended in water, the suspension is made alkaline by the addition of 2 n; ammonia- title compound
iCcl with jiv. - ----- - -
It is filtered off and recrystallized from ethyl acetate after cooling.
Yield 1.0 g (12% of theoretically calculated value). T. pl.
360 C.
Example. 6. 7-Metsh1-2- (4- -pyridazinyl) -6,7-DIGIDRO-3N-5H-pyrrolo 2,3-benzimidazol-6-one.
By analogy with example 5, when using as starting substances 6.0 g (24 mmol) of 5,6-diamino-3-methylindolin-2-one in the form of dihydrochloride and 3.6 g (28.8 mmol) pi-, ridazine-4-carboxylic acid, the title compound is obtained. Purification is performed by chromatography on a column filled with silica gel (eluent, mixture of methylene chloride and methyl alcohol in the ratio
9: 1).
Yield 0.15 g (2.4% of theoretical calculated value). T. pl. 340 ° C. Example 7. 7,7-Dimetsh1-2- (5-pyrimidinyl) -6,7-dihydro-3N, 5H- -pyrrolo G2,3-fj benzimidazol-6-one.
The example is carried out analogously to example 5, using 0.164 g, (1.32 mmol) pyrimidine-5-carboxylic acid and 0.191 g (1 mmop) of 5.6-diamino-3,3-da1methylindoline- 2-she obtained, after cyclization of the crude product with glacial acetic acid, the title compound.
An example.
5 - (4-piri oadinyl) -6,7-dihydro-3N, 5H
-PIR1ULo 2,3-fJ benzimidazol-6-one.
The example is carried out by analogy with example 1, when used as the starting materials 60 mg (0.55 mol) pyrimidine-4-aldehyde and 0.103 g (0.54 mmol) of 5,6-diamino-3, 3-dimethylin-2-one is obtained, after chromatography on a column filled with silica gel (eluent: mixture of methylene chloride and methyl alcohol in the ratio 9: 1), indicated in the heading
compound.
Yield 10 mg (6.6% of theoretically calculated value). T. piece
. - MS
20
-7 300 ° C.
Example 9. 7,7-Dimethyl-2- - (2-methylpyrimidine-5-1 OT) -6,7-digi 25 ro-3N, 5H-pyrrolo | 2,3-€ benzimidazOL-6-OH.
Analogously to Example 5, when using as starting materials 5.7 g (C O MMOftb) 5,6-diamino-3,3-dimethylindolin-2-one and 4.8 g (35 mmol) 2-methylpyrimidine-5 -kar new acid get monoamide.
Yield 3.6 g (39% of the theoretical value), m.p. sixteen
f f
35
40
45
 (of water) .
Immediately after this, the non-purified product is cyclized with glacial acetic acid to give the title compound.
The output of 2.3 g (68.5% of the theoretical value of the calculated value), T. pl
350 C ,,
Example 10. 7,7-Dimethyl- (4-imidazolyl) -6,7-dihydro-3H, 5-pyrrolo 2,3-benzimidazsh-6-one By analogy with example 3, when used as the starting c. Substances of 2.7 g (14.1 mmol) of 5,6-dieno-3,3-dimeshshndolin-2-one and 2, 50 (21 5 mmol) of the imide-4-carboxylic acid chloride are obtained in the title compound.
Yield 0.17 g (4.5% of the calculated value theory), T. n (from methyl alcohol),
Example 11. 7,7-Dimethyl- (6-hydroxyfidazin-3- "l) -6,7-digi
8. 7,7-Dimethyl-2 Example.
- (4-pyri oadinyl) -6,7-dihydro-3N, 5H-PIR1Yulo 2,3-fJ benzimidazol-6-one.
The example is carried out by analogy with example 1, using 60 mg (0.55 mol) pyrimidine-4-aldehyde and 0.103 g (0.54 mmol) of 5,6-diamino-3.3 when using as the starting materials. -dimethylin-valley-2-one is obtained, after chromatography on a column filled with silica gel (eluent: mixture of methylene chloride and methyl alcohol in a ratio of 9: 1), the title
compound.
Yield 10 mg (6.6% of theoretically calculated value). T. pieces
. - MS
0
-7 300 ° C.
Example 9. 7,7-Dimethyl-2- - (2-methylpyrimidine-5-1 OT) -6,7-dihyd-25 ro-3N, 5H-pyrrolo | 2,3-€ benzimidazOL-6-OH.
Analogously to example 5, when using as starting substances 5.7 g (C O MMOftb) 5,6-diamino-3,3-dimethylindolin-2-one and 4.8 g (35 mmol) 2-methylpyrimidine-5- Carboxylic acid, monoamide is obtained.
Yield 3.6 g (39% of the theoretically calculated value), m.p. 166f f
35
40
45
 (of water) .
Immediately thereafter, the crude product is subjected to cyclization with glacial acetic acid, whereby the title compound is obtained,
Input 2.3 g (68.5% of the theoretically calculated value), m.p.
350 C ,,
Example 10. 7,7-Dimethyl-2- (4-imidazolyl) -6,7-dihydro-3H, 5H-pyrralo 2,3-benzimidazsh-6-one. By analogy with example 3, when using as starting substances 2.7 g (14.1 mmol) of 5,6-diamino-3,3-dimeshshndolin-2-one and 2, g 50 (21 5 mmol) acid imidazole-4-carboxylic acid is obtained in the title compound.
Yield 0.17 g (4.5% of the theoretically calculated value), m.p. (from methyl alcohol),
Example 11. 7,7-Dimethyl 2- - (6-hydroxyfidazin-3- "l) -6,7-dihydro714
-ZH, 5H-pyrralo | 2,3-benzimidazol-6-one.
By analogy with example 5, when using as starting materials, 4.9 g (35 mmol) of 6-hydroxypyridazine-3-carboxylic acid and 5.7 g of I (30 mmol) of 5,6-diamino-3, 3-dimethyl-I ind6lin-2-one gives the compound indicated in I the title.
I Yield 258 g (32% of the theoretically I calculated value), T. pl. (from ethyl alcohol).
Example 12. 7,7-Dimethyl 2- - (1,2,4-1H-triazol-3-yl) -6,7-dihydro-3N, 5H-chfrolo 2, 3-7benzimidazal-6-one .
By analogy with example 1, when using as starting compounds, I Institute 0.38 g (2 mmop) 5,6-diamino-I-3,3-dimethylindolin-2-one and 0.195 g I (2 mmol) 1, 2,4-triazole-3-apdehyde get the compound crazed in the title.
Yield: 0.15 g (28% of theoretically calculated value). T. pl. 350 ° C.
I Example 13. 7,7-Dimetsh1-2-; - (2-metsh10xazo-4-yl) -6., 7-dihydro: -ZH, 5H-tetra-C2,3-f ben; Schmidazole-I-6-one.
By analogy with example 9, when using as starting materials, 764 mg (4 mmol), 3,6-diamino-3,3-dimeshshndopin-2-one and 672 mg (5.32 mmol) 2-methyloxazol-4-carbo i new acid, after purification on silica gel (eluting agent: a mixture of methylene chloride and methyl alcohol j in a ratio of 8: 2), get
the title compound. Yield 0.3 g 426.6% of the theoretically calculated value). T. pl. 315-318 C.
Example 14. 7,7-Dimethyl-2- - (5-methylpyrazse-3-Sh1) -6,7-dihydro-3H, 5H-PIRROLO {2,3-f7 benzimidazole-b-one.
By analogy with example 1. and when used as starting materials, 0.57 g (3 mmol) of 5,6-diamino-3,3-dimethylindapin-2-one and 0.33 g (3 mmol) of 5 metipyrazo -3-aldehyde | And after alkalizing the reaction mixture with concentrated ammonia solution, the title compound is obtained as a crude product. The crude product is purified on silica gel (elu8
Chemical agent: a mixture of methylene chloride and ammonia-saturated methyl alcohol in a ratio of 10: 3)
Yield 0.22 g (26% of theoretically calculated value). T. pl. 245-250 ° С (out of water).
Analogously to examples 1-14, these pyrrolobenzimidazoles are obtained:
15)), 7-Dimethyl-2- (2-fusion) - 6,7-dihydro-3H, 5H-pyropolot2,3-f Dben zimidazop-6-one, T. pl. 311-316 C (from ethyl acetate / methanol)}
16) 7-Methyl-7-ethoxycarbonyl-2- (2-pyrazinyl) -6,7-dihydro-3N, 5H-pyrrolo 2,3-benzimidazole-6-one, mp. 288-290 ° C;
17) 7,7-Dimethyl-2- (2-thienylmethyl) 6.7 dihydro-3N, 5H-pyrroloG2,3-
benzimidazod-6-one, T. pl. 233-235 s (column chromatography),
18) 7,7-Dimetsh1-2- (1,2,3, -thiadiazol-4-yl) -6,7-dihydro-3N, 5H-pyro-, 3-f7 benzimidazol-6-one, T. square
 (from isopropyl alcohol) j
19) 7,7-Dimetsh1-2- (1,2,3-thiadia) -6,7 dihydro-3N, 5H-pyrro, 3-f benzimidazol-6-one, T. nl. 286-290 ° С (from methanol) J
20) 7,7-Dymetsh1-2- (1,2,5-thiadiazol-3-yl) -6,7-dihydro-3N, 5 | H-pyrrolo t2,3-fZbenzimidazol-b-on, T .pl.
UZ00 ° C5
21) 7,7-Dimetsh1-2- (2-methylmercapto 1,3,4-oxadiaz olt-5-yl) -6,7-dihydro-3H, 5H-pyrpolot2,3-f benzimidazol-6- - he, T. pl. 311 ° C (methanol)}
22) 7,7-dimethyl- -2- (4-carboxy-1,2,3-1H-triazol-5- -yl) -6,7-dihydr0-3H, 5H-PIRPolo C2,3 -f benzimidazole dihydrochloride -6-she, T. pl. ZOO C (isopropanol),
23) Hydrochloride 7.7 gDimetsh1-2- (4-methoxycarbonyl-1,2,3-1H-triazol-5-yl) -6,7-dihydro-3N, 5H-pyrro, 3-benzimidazole-6 -one, T. pl. 300 ° Ci
24) 7-Ethyl-2- (4-pyridazinyl) -6,7- -dihydro-3N, 5H-pyrrolo 2,3-f benzimidazol-6-one, T. pl. 300 ° C (chromatography on an ether / methanol vinegar column) J
25) 2 - (4-pyridazinyl) -spiro-cyclopentane-1,7-6, 7 -dihydro-3 H, 5 H- -pyrrapo 2,3-1benzimidazole -b-one, m.p. 365-367 C (dioxane: water 1: 1)
The results of pharmacological tests of new pyrrolobenzimidazoles.
91
Research methodology. Male rats Spraque-Dawley (weighing about 350-450 g) were used as experimental animals, which were anesthetized by intraperitoneal injection of a barbiturate, after which a catheter was measured into the left ventricle of the heart through an artery carotis dextra (Millae Mikrotip diameter 0.5 mm). Through this sensor, the pressure of blood inside the left ventricle was continuously recorded, a polypropylene catheter was inserted into the jugulasis vein for intravenous administration of the compounds, and another polypropylene catheter was inserted into the abdominal aorta through the artery of the feiaora-lis and the ECG was removed by subcutaneously inserted electrodes.
During the preparation of the animal, as well as throughout the subsequent test period, the rats were fixed on an electrically heated and thermostatically controlled operating table.
The test compounds were always administered intravenously, the injection volume of the compound injected being 1 ml / kg body weight. For periods of 10 minutes, intravenously increasing doses were administered from 0.01 to 30 mg. Based on the recorded data, a curve is obtained showing the effect of the doses of the compound studied.
With the aid of measured parameters, the equopotential doses for a positive inotropic effect (dp / / dt) were calculated by regression. In addition, the maximum effect (or dp / dt) achieved was found as a criterion for the strength of the compound and the corresponding dose of the compound.
The table shows the relationship of equipotential doses (doses in mg / kg, leading to an increase in the force of contraction of the heart 1.5 m Hg / s) and the maximum force of action (W max to the maximum increase in the force of contractions dp / dt in the calculation to the original value). The respective dose of compound given is indicated in parentheses.

ten
Pyrrolobenzimidazolone test results

As can be seen from the data table,
The compounds according to examples 6.8 and 1 are the strongest compounds of this group, with the compounds Ref 1. and Ref 2, Ref 1 being stronger: 3-amino-6-methyl-5-phenyl-2 (1H) -pyr - redine methane ulfonat; Ref 2 3,4-dihydrog-6- - (3,4-dimethoxybenzoyl) - 1-piperazinip / -2 (1H) -quinolinone.
New pyrrolobenzimidazoles can be classified as low-toxic substances, since testing them on a living model did not reveal any negative effects on a living organism.

权利要求:
Claims (1)
[1]
Invention Formula
The method of producing pyrrolobenzimidazoles of general formula
BUT
Hel-X-
where R is hydrogen or methyl
R is hydrogen, methyl, ethyl or ethoxycarbonyl,
nl R and R-i together form tetramethylene;
line valence or methyl ene group; residue pyrrole, thiophene, imidazole, thiazole, oxa Zopa, triazole, pyrazine, pyrimidine, pyridazine, thiadiazole, furan, Het oksiX pyridazine metilpirimidi- on, metiloksazopa methyl merkaptooksadiazola, Karbokam sitriazola, methoxycarbonyl shiggriazola metilpira- or ash,
and (whether their tautomers or their physiological compatible salts of inorganic acids, characterized in that the compound total RI
where nd and R have the indicated meanings, are reacted with a compound of the formula
Hei-x c
about
ten
where X and Het have the indicated values of f Y is hydrogen or halogen, or the group
15
-O-C
NCeHn
Seen
followed by direct cyclization and the desired product is made in free form or in the form of its physiologically compatible inorganic acid salt.

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1470191A3|1989-03-30|Method of producing pyrrolobenzimidazols or their tautomers, or their physiologically compatible salts of inorganic acids

---

US4954498A|1990-09-04|Tricyclic benzimidazole compounds, pharmaceutical compositions and methods of use

---

EP0966454A1|1999-12-29|Disubstituted bicyclic heterocycles, their production and use as medicaments

---

WO1993008169A1|1993-04-29|Substituted aminopyrimidines as angiotensine ii antagonists

---

IL93073A|1994-05-30|cis-2,7- disubstituted-octahydro-1h- pyrido | pyrazines and anxiolytic and antidepressant pharmaceutical compositions containing them

---

DE3347290A1|1985-07-11|NEW 2-PHENYL IMIDAZOLES, THEIR PRODUCTION AND MEDICINES CONTAINING THESE COMPOUNDS

---

EP0733052B1|2000-09-27|Bicyclene derivatives, their production and use

---

RU2233278C2|2004-07-27|Pyrimidine compounds, method for their preparing and pharmaceutical composition

---

HU193581B|1987-10-28|Process for producing amino-pyrimidine derivatives and pharmaceutical compositions containing them

---

NZ203956A|1985-11-08|Imidazo|pyridine derivatives and pharmaceutical compositions

---

US4351832A|1982-09-28|2-|-4-pyrimidinamines

---

FI93444C|1995-04-10|Process for the preparation of therapeutically active dihydropyridine derivatives

---

US5328910A|1994-07-12|Sino-atrial node modulating pyrrolopyrimidines

---

NZ201659A|1984-07-31|Benz-amino-1,2,4,5-tetrahydroimidazo|-quinazolin-2-ones

---

GB2121037A|1983-12-14|2|-pyridinone derivatives their preparation and pharmaceutical compositions containing them

---

CA1092108A|1980-12-23|Oxadiazolopyrimidine derivatives

---

DE69915514T2|2005-01-05|Prenyl INHIBITORS

---

EP0207483B1|1992-03-18|Benzimidazoles, process for their preparation, medicaments containing them and intermediates

---

HU193067B|1987-08-28|Process for the production of new pyridazinon-derivatives and of their salts

---

DE3346640A1|1985-07-04|NEW IMIDAZOLE DERIVATIVES, THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS

---

CN108164506B|2021-03-16|DPP-4 enzyme inhibitor and preparation and application thereof

---

KR900000671B1|1990-02-02|2,2-bi-1h-imidazoles and their preparation

---

EP0240026A1|1987-10-07|Heterocyclically substituted benzimidazoles, method for their preparation and medicines containing these compounds

---

EP1945304A2|2008-07-23|Imidazo-pyridine containingbeta agonists, method for producing them and their use as drugs

---

DE4341663A1|1995-06-08|New bi:cyclic piperazinone carboxamide, carboxylic or sulphonic ester

同族专利:

---

公开号 | 公开日

---

ZA86360B|1986-09-24|

---

EP0189103A2|1986-07-30|

---

FI81579C|1990-11-12|

---

AU5224586A|1986-07-24|

---

DE3676313D1|1991-02-07|

---

FI860228A0|1986-01-17|

---

EP0189103B1|1991-01-02|

---

FI860228A|1986-07-19|

---

ES8900123A1|1989-01-16|

---

AT59649T|1991-01-15|

---

US4695567A|1987-09-22|

---

IL77582A|1990-01-18|

---

DK20786A|1986-07-19|

---

ES557777A0|1989-01-16|

---

DE3501497A1|1986-07-24|

---

JPS61167689A|1986-07-29|

---

ES551002A0|1988-03-01|

---

FI81579B|1990-07-31|

---

ES8801832A1|1988-03-01|

---

DD253620A5|1988-01-27|

---

HU194242B|1988-01-28|

---

GR860144B|1986-05-16|

---

AU580832B2|1989-02-02|

---

EP0189103A3|1987-12-23|

---

HUT41791A|1987-05-28|

---

DK20786D0|1986-01-16|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

IN148930B|1977-09-19|1981-07-25|Hoffmann La Roche|

---

EP0033612B1|1980-02-02|1984-04-11|Beecham Group Plc|Pyrano derivatives, a process for their preparation and antihypertensive compositions containing them|

---

US4359465A|1980-07-28|1982-11-16|The Upjohn Company|Methods for treating gastrointestinal inflammation|

---

US4548946A|1981-03-26|1985-10-22|E. I. Du Pont De Nemours And Company|Antiinflammatory and/or analgesic 1,8-Dihydro--8-aryl-2-[thio]-indeno[1,2-d]imidazoles and their corresponding sulfoxides and sulfones|

---

DE3224512A1|1982-07-01|1984-01-05|Dr. Karl Thomae Gmbh, 7950 Biberach|NEW IMIDAZOLE DERIVATIVES, THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS|

---

GB8307865D0|1983-03-22|1983-04-27|Fujisawa Pharmaceutical Co|Benzimidazole derivatives|

---

DE3410168A1|1984-03-20|1985-09-26|Boehringer Mannheim Gmbh, 6800 Mannheim|Novel isochinoline diones, process for their preparation, medicaments containing these compounds and intermediates|

---

PL147842B1|1984-05-12|1989-08-31|Method of obtaining novel pyroisobenzimidazoles|

---

US4552876A|1984-07-09|1985-11-12|Usv Pharmaceutical Corp.|Bisbenzoxazines and pharmaceutical use|

---

DE3445669A1|1984-12-14|1986-06-19|Boehringer Mannheim Gmbh, 6800 Mannheim|NEW PYRROLO-BENZIMIDAZOLES, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS|DE3445669A1|1984-12-14|1986-06-19|Boehringer Mannheim Gmbh, 6800 Mannheim|NEW PYRROLO-BENZIMIDAZOLES, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS|

---

DE3531678A1|1985-09-05|1987-03-12|Boehringer Mannheim Gmbh|NEW PYRROLO-BENZIMIDAZOLES, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS|

---

DE3626664A1|1986-08-07|1988-02-11|Boehringer Mannheim Gmbh|TRICYCLIC BENZOTRIAZOLES, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS|

---

DE3639466A1|1986-11-18|1988-05-19|Thomae Gmbh Dr K|NEW PYRROLO-BENZIMIDAZOLES, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF|

---

DE3642315A1|1986-12-11|1988-06-23|Boehringer Mannheim Gmbh|NEW PYRROLOBENZIMIDAZOLES, PROCESS FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS|

---

DE3701277A1|1987-01-17|1988-07-28|Boehringer Mannheim Gmbh|NEW TRICYCLIC BENZIMIDAZOLES, METHOD FOR THEIR PRODUCTION AND USE AS MEDICINAL PRODUCTS|

---

DE3706427A1|1987-02-27|1988-09-08|Boehringer Mannheim Gmbh|NEW SUBSTITUTED 3H-INDOLES, INTERMEDIATE PRODUCTS, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS|

---

DE3740985A1|1987-12-03|1989-06-15|Boehringer Mannheim Gmbh|USE OF LINEAR FURNISHED TRICYCLES AS AN INHIBITORS OF THE ERYTHROCYTE AGGREGATION|

---

US4963677A|1987-12-30|1990-10-16|Orion Corporation Ltd.|Heterocyclic lactam compounds|

---

AT138658T|1987-12-30|1996-06-15|Orion Yhtymae Oy|HETEROCYCLIC COMPOUNDS|

---

DE3803775A1|1988-02-09|1989-08-17|Boehringer Mannheim Gmbh|NEW SUBSTITUTED LACTAME, METHOD FOR THE PRODUCTION THEREOF, AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS|

---

DE3809868A1|1988-03-24|1989-10-05|Boehringer Mannheim Gmbh|NEW HETEROCYCLICALLY SUBSTITUTED 5,7-DIHYDRO-PYRROLOBENZOXAZOL-6-ONE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS|

---

DE4027592A1|1990-08-31|1992-03-05|Beiersdorf Ag|NEW PYRROLOBENZIMIDAZOLE, IMIDAZOBENZOXAZINONE AND IMIDAZOCHINOLONE, PROCESS FOR THEIR PREPARATION AND THEIR USE AND THE COMPOUNDS CONTAINING PREPARATIONS|

---

US7285569B2|2004-09-24|2007-10-23|Hoff Hoffmann-La Roche Inc.|Tricycles, their manufacture and use as pharmaceutical agents|

---

TW200626149A|2004-09-24|2006-08-01|Hoffmann La Roche|Tricycles, their manufacture and use as pharmaceutical agents|

---

US20060142247A1|2004-12-17|2006-06-29|Guy Georges|Tricyclic heterocycles|

---

CN101160312A|2005-04-14|2008-04-09|霍夫曼-拉罗奇有限公司|Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents|

---

BRPI0608178A2|2005-04-14|2009-11-17|Hoffmann La Roche|aminopyrazole derivatives, their manufacture, pharmaceutical composition and use as pharmaceutical agents|

---

US20090143375A1|2005-12-15|2009-06-04|F. Hoffmann-La Roche Ag|Tricyclic Lactam Derivatives, Their Manufacture and Use as Pharmaceutical Agents|

---

BRPI0709082A2|2006-03-23|2011-06-28|Hoffmann La Roche|substituted indazole derivatives, their manufacture and use as pharmaceutical agents|

---

SG11201501923WA|2012-09-13|2015-04-29|Hoffmann La Roche|2-oxo-2,3-dihydro-indoles for the treatment of cns disorders|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

DE19853501497|DE3501497A1|1985-01-18|1985-01-18|NEW PYRROLO-BENZIMIDAZOLES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND INTERMEDIATE PRODUCTS|

---